IW 3718

Drug Profile

IW 3718

Alternative Names: IW-3718

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastro-oesophageal reflux

Most Recent Events

  • 12 Aug 2015 Ironwood Pharmaceuticals completes a phase IIa trial in Gastro-oesophageal reflux in USA (NCT02030925)
  • 05 Aug 2015 Ironwood Pharmaceuticals plans a phase IIb trial in Gastro-oesophageal reflux disease (Treatment-experienced) in USA (PO) (NCT02637557)
  • 04 Feb 2015 Top-line efficacy and adverse events data from a phase IIa trial in Gastro-oesophageal reflux released by Ironwood Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top